Evidence map›Paper›PMID 36111560›Full record

ArticleThe Journal of infectious diseases2022

Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity.

Annika Rössler, Janine Kimpel, Verena Fleischer, Silke Huber, Dorothee von Laer, Wegene Borena, Reinhard Würzner, HEVACC Study Group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Avidity maturation of anti-spike IgG after vaccination in COVID-19 convalescent vs COVID-19 naïve patients.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annika RösslerInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-5298-0288
Janine KimpelInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-5210-7905
Verena FleischerInstitute of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
Silke HuberInstitute of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-7021-1845
Dorothee von LaerInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-5825-7237
Wegene BorenaInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-8011-5825
Reinhard WürznerInstitute of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-6804-442X
HEVACC Study Group

Funding

Austrian Science Fund FWF HOROS W-1253
6 · The paper itself

Abstract

We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of the mRNA vaccine BNT162b2.

Indexed as

Antibody AffinityBNT162 VaccineChAdOx1 nCoV-19COVID-19AdenoviridaeHumansKineticsSpike Glycoprotein, CoronavirusVaccinationBNT162 VaccineChAdOx1 nCoV-19Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody kineticsavidityheterologous vaccinationSARS-CoV-2

Identifiers

PMID36111560
PMCPMC9494481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.